VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Valion Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.16−0.01 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $3.92M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Valion Bio's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $28.45K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jason Jagessar | 440,242 | 9.99% | 13G (passive) | Jun 8, 2026 |
| Maier J. Tarlow | 2,102,780 | 9.90% | 13D (active) amendment | Aug 20, 2026 |
| 3i Management LLC | 132,671 | 9.90% | 13G (passive) amendment | Sep 4, 2026 |
| 3i, LP | 132,671 | 9.90% | 13D (active) amendment | Sep 3, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dean Zikria | Interim CEO, Director | – | – | Sep 24, 2026 |
| Michael K. Handley | Chief Executive Officer, Director | 11,030 | 0.05% | May 20, 2026 |
| Jennifer Ernst | Chief Executive Officer, Director | 37,953 | 0.17% | Dec 22, 2025 |
| Lisa G. Wolf | COO & CFO | 27 | 0.00% | Sep 24, 2026 |
| Melinda Lackey | General Counsel & SVP of Legal | – | – | May 4, 2026 |
| Blake Gurfein | Chief Scientific Officer | 119,979 | 0.54% | Dec 20, 2024 |
| Jared David Malbin | Director | – | – | Sep 17, 2026 |
| Thomas Jensen | Director | – | – | Sep 17, 2026 |
| Sheryle Bolton | Director | 10,000 | 0.05% | Apr 20, 2026 |
| Christina Rizopoulos Valauri | Director | 19,000 | 0.09% | Apr 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lisa G. Wolf COO & CFO | Sep 18, 2026 | Tax withholding | −2 | $2.12 | $4 | 27 |
| Lisa G. Wolf COO & CFO | Sep 18, 2026 | Option exercise | +4 | – | – | 29 |
| Lisa G. Wolf Chief Financial Officer | Jun 18, 2026 | Option exercise | +92 | – | – | 618 |
| Michael K. Handley Chief Executive Officer, Director | May 18, 2026 | Option exercise | +2,206 | – | – | 11,030 |
| Sheryle Bolton Director | Apr 15, 2026 | Buy | +10,000 | $1.04 | $10.40K | 10,000 |
| Christina Rizopoulos Valauri Director | Apr 1, 2026 | Buy | +19,000 | $0.95 | $18.05K | 19,000 |
| Lisa G. Wolf Chief Financial Officer | Mar 18, 2026 | Option exercise | +92 | – | – | 526 |
| Michael K. Handley Chief Operating Officer | Feb 18, 2026 | Option exercise | +8,824 | – | – | 8,824 |
| Lisa G. Wolf Chief Financial Officer | Dec 18, 2025 | Option exercise | +736 | – | – | 736 |
| Lisa G. Wolf Chief Financial Officer | Dec 18, 2025 | Tax withholding | −302 | $1.87 | $565 | 434 |
| Jennifer Ernst Chief Executive Officer, Director | Dec 18, 2025 | Option exercise | +14,706 | – | – | 37,953 |
| Jennifer Ernst Chief Executive Officer, Director | Dec 18, 2025 | Tax withholding | −5,262 | $1.87 | $9.84K | 32,691 |
| Jennifer Ernst Chief Executive Officer, Director | Sep 22, 2025 | Award | +22,541 | – | – | 23,247 |
| Kimberly Ann Bambach Interim CFO | Mar 12, 2024 | Award | +7,500 | – | – | 7,500 |
| Karen Drexler Director | May 16, 2022 | Other | −15,111 | – | – | 18,076 |
| Jennifer Ernst Chief Executive Officer, Director, 10% owner | Nov 12, 2021 | Conversion | +1,391 | – | – | 1,172,891 |
| Jennifer Ernst Chief Executive Officer, Director, 10% owner | Nov 12, 2021 | Conversion | +26,986 | – | – | 1,199,877 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.